Category: Price hikes

Union households: lawmakers must protect our pharmacy benefits

New research out today from CAPD, conducted by Hart Research Associates, shows how strongly union households value their…

Conservatives Agree: Restricting Pharmacy Benefits Will Harm Patients, Taxpayers

GOP candidates will soon take the stage for one of the biggest political moments of the year: the…

Big Pharma is Playing a Dangerous Game with GLP-1s

It’s hard to miss the recent headlines about new weight-loss drugs like Ozempic and Wegovy. Called GLP-1s, these…

How Big Pharma’s Product Hops Hurt HIV/AIDS Care

Over the last twenty years, new medications have dramatically changed the fight against HIV/AIDS. These medications – called…

Big Pharma really doesn’t mind if the government picks winners and losers – so long as it is always the winner.

We took note of two recent POLITICO articles that make very, very clear the reality of what’s going…

PBMs as Negotiators

Rhetoric in Washington, DC around high and rising drug prices continues to intensify. As Congress considers potential legislation,…

Partial Transparency is No Transparency at All

Although Congress has devoted much attention to exploring pharmaceutical manufacturers and pharmacy benefit managers, less attention has been…

Reason: Patient Privacy at Risk in S. 127

As Congress returns for a new work period, both parties are renewing their focus on how to bring…

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition

Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat…

House Advances CAPD-Supported Measures to Lower Drug Prices for Patients

Americans have overwhelmingly supported action by Congress to lower Big Pharma’s drug prices for years, and now –…